BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 10347283)

  • 21. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors.
    Halling KC; Scheithauer BW; Halling AC; Nascimento AG; Ziesmer SC; Roche PC; Wollan PC
    Am J Clin Pathol; 1996 Sep; 106(3):282-8. PubMed ID: 8816583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
    Friedrich RE; Nörnberg LKN; Hagel C
    Anticancer Res; 2022 May; 42(5):2327-2340. PubMed ID: 35489721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients.
    Leroy K; Dumas V; Martin-Garcia N; Falzone MC; Voisin MC; Wechsler J; Revuz J; Créange A; Levy E; Lantieri L; Zeller J; Wolkenstein P
    Arch Dermatol; 2001 Jul; 137(7):908-13. PubMed ID: 11453810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors.
    Mawrin C; Kirches E; Boltze C; Dietzmann K; Roessner A; Schneider-Stock R
    Virchows Arch; 2002 Jun; 440(6):610-5. PubMed ID: 12070601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plexiform malignant peripheral nerve sheath tumor of infancy and childhood.
    Meis-Kindblom JM; Enzinger FM
    Am J Surg Pathol; 1994 May; 18(5):479-85. PubMed ID: 7513502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog.
    Carbonnelle-Puscian A; Vidal V; Laurendeau I; Valeyrie-Allanore L; Vidaud D; Bièche I; Leroy K; Lantieri L; Wolkenstein P; Schedl A; Ortonne N
    Hum Pathol; 2011 Mar; 42(3):434-43. PubMed ID: 21193222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis.
    Koga T; Iwasaki H; Ishiguro M; Matsuzaki A; Kikuchi M
    J Pathol; 2002 May; 197(1):98-107. PubMed ID: 12081210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.
    Brosius SN; Turk AN; Byer SJ; Brossier NM; Kohli L; Whitmire A; Mikhail FM; Roth KA; Carroll SL
    Acta Neuropathol; 2014 Apr; 127(4):573-91. PubMed ID: 24232507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutation analysis of malignant peripheral nerve sheath tumors.
    Verdijk RM; den Bakker MA; Dubbink HJ; Hop WC; Dinjens WN; Kros JM
    J Neuropathol Exp Neurol; 2010 Jan; 69(1):16-26. PubMed ID: 20010306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant peripheral nerve sheath tumors of the spine: results of surgical management from a multicenter study.
    Chou D; Bilsky MH; Luzzati A; Fisher CG; Gokaslan ZL; Rhines LD; Dekutoski MB; Fehlings MG; Ghag R; Varga P; Boriani S; Germscheid NM; Reynolds JJ;
    J Neurosurg Spine; 2017 Mar; 26(3):291-298. PubMed ID: 27834629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.
    Nielsen GP; Stemmer-Rachamimov AO; Ino Y; Moller MB; Rosenberg AE; Louis DN
    Am J Pathol; 1999 Dec; 155(6):1879-84. PubMed ID: 10595918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.